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Background: To investigate whether a modified Rheumatoid Arthritis Disease Activity Index-5 could be applied as
a routine assessment tool for psoriatic arthritis (PsA) patients.
Methods: Ninety-seven PsA outpatients (mean age 49.78 years; age range 23–80 years; 49 male, 48 female),
completed a prototype questionnaire. Tender and swollen joint counts, including enthesiopathy, physician’s
assessment of disease activity on a visual analog scale (MDglob), erythrocyte sedimentation rate, and patient
satisfaction with disease status (PatSat: 1 = excellent to 5 = unsatisfactory) were recorded. Factorial analysis was
performed and alpha, as a measure of reliability, and tau were calculated. The ultimate five-item questionnaire,
calculated by (Q1 + Q2 + Q3 + Q4 + Q5)/5, was then handed over to 152 PsA outpatients (mean age 54.02 years;
age range 26–80 years; 82 male, 70 female), and analyzed accordingly.
Results: Analyzing the internal consistency of the prototype questionnaire revealed the highest alpha value of
0.849, on deleting the question targeting disease course. Alpha for the final Stockerau Activity Score for Psoriatic
Arthritis (SASPA) was 0.875, with all items contributing to the final result (item loading from 0.573 to 0.910).
Kendall’s tau for the relationship between SASPA scores and swollen joint count, tender joint count, and MDglob
was 0.34, 0.416, and 0.392, respectively. The sensitivity of the questionnaire to change was demonstrated in patients
starting treatment with a tumor necrosis factor blocker (standardized mean difference: 2.1).
Conclusion: The SASPA questionnaire constitutes a fully patient-administered tool to monitor PsA activity. Its
reliability, convergent validity, and sensitivity to change were demonstrated.
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Psoriatic arthritis (PsA) frequently joint causes destruc-
tion and functional impairment, although its course is
generally less aggressive than that of rheumatoid arthritis
(RA) [1]. Peripheral joint damage is significantly greater
in RA than in PsA after an equivalent duration, however,
joint function and quality of life scores frequently indi-
cate the same amount of impairment for both diseases,* Correspondence: burkhard.leeb@stockerau.lknoe.at
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ease in PsA [2].
Hence, in some patients, PsA management requires
treatment regimens comparable with those of RA [3].
Given the recent developments for the treatment of PsA,
remission and minimal disease activity are postulated as
treatment goals and may represent a measure to com-
pare therapies [4]. The treat-to-target approach claims
to have a better patient outcome [5], which is currently
the object of clinical trials [6]. It is one of the overarch-
ing principles of this approach that therapy should be
based on a shared decision between patient and rheuma-
tologist [5].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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published, however, because of a lack of consensus; they
are not widely utilized [7]. The Disease Activity Score
(DAS28-ESR and DAS28-CRP), Simplified Disease Ac-
tivity Index (SDAI), Composite Psoriatic Disease Activity
Index (CPDAI), disease activity in psoriatic arthritis
(DAPSA), and Psoriatic Arthritis Disease Activity Score
(PASDAS) have been proposed [8-12]. Although vali-
dated only for RA, DAS28 and the original DAS (also in-
cluding the feet) have already been used in PsA clinical
trials as secondary efficacy criteria [8,13]. However,
DAS28 appears to be explicitly different statistically when
applied to PsA patients [14].
Recently, good concurrent validity and discriminant
capacity of these disease activity indices were observed,
but the proportions of patients classified at the disease
activity levels differed. In particular, the number of pa-
tients in remission clearly differed among the respective
indices [7], indicating that the interchangeability of those
indexes is limited.
All those indexes are appropriate for comparisons at
the group level, but may not be fully suitable for asses-
sing individual patients. It is crucial for personalized
daily patient management, particularly when following
the treat-to-target approach [5], to be aware of the pa-
tient’s view at any time.
Also, several response criteria, mainly the Psoriatic
Arthritis Response Criteria (PsARC) or the modified
American College of Rheumatology (ACR) response cri-
teria, have been proposed and subsequently applied in
clinical trials to record disease activity and therapeutic
efficacy, respectively [15,16]. These tools give relative re-
sults with respect to a baseline observation, which, as in
routine RA management, can be regarded as an essential
reason why those criteria are considered not to meet the
needs of daily rheumatologic practice.
Within the field of RA monitoring it is accepted that
patient questionnaires for functional status could be
more informative when pertaining to prognosis than
even a full joint count [17]. It was shown that the three
patient-only parameters in the ACR response criteria,
namely physical function, pain and global status, were as
reliable as the whole core set for describing RA activity
changes, and could constitute the basis for therapeutic
decisions [18]. In addition, an index of those three self-
report scales on the ACR core data set can discriminate
between active and placebo treatments in clinical trials,
as well as the DAS score [19].
We have demonstrated that a modified version of the
Rheumatoid Arthritis Disease Activity Index (RADAI),
RADAI-5, refraining from joint counts, can measure RA
activity in daily routine with high reliability and proven
convergent validity [20]. The time required for RADAI-5
is <30 sec. This enhances its feasibility, which apart fromreliability and validity is the most important prerequisite
for daily routine application [21].
Keeping in mind the dilemma with accurate monitor-
ing of patients, it 12891_2015_512med reasonable for us
to transfer the concept of the RADAI-5 to PsA. The ul-
timate intention was to devise a fully patient-administered
tool to measure PsA activity in daily routine.
Methods
Prototype questionnaire
RADAI-5 was established in the German language and
comprises five items in a Likert format from 0 to 10
[22]. The respective questions are “How active was your
arthritis in the last 6 months?” (0 = completely inactive
to 10 = extremely active); “How active is your arthritis
today with respect to joint tenderness and swelling?” (0 =
completely inactive to 10 = extremely active); “How severe
is your arthritis pain today?” (0 = no pain to 10 = unbear-
able pain); “How would you describe your general health
today? (0 = very good to 10 = very bad); and “Did you ex-
perience joint (hand) stiffness on awaking yesterday morn-
ing? If yes, how long was this stiffness?” (0 = no stiffness to
10 = stiffness the whole day). In contrast, to the rather
complicated formula of the original RADAI, the result can
be easily calculated: (Q1 +Q2 +Q3 +Q4 +Q5)/5 [13]. For
PsA patients, one question targeting patient’s assessment
of skin involvement was added; “How active do you regard
your skin disease? (0 = completely inactive to 10 = ex-
tremely active).
The intention behind the adaptation of RADAI-5 for
assessment of PsA was that the five questions of the
RADAI-5 cover five of six domains, being part of the
OMERACT (Outcome Measures in Rheumatology) core
set for PsA evaluation, namely joints, function, pain, pa-
tient’s global assessment, and quality of life [23], whereas
the new sixth question explicitly targets the skin. We
hypothesized that important domains of PsA activity as-
sessment, such as enthesitis, dactylitis, and nail involve-
ment are also at least in part covered by the questions
targeting arthritis, pain and skin [24].
All patients gave their informed consent to be enrolled
into this observational study, which was performed ac-
cording to the Declaration of Helsinki. No objection
against the study design was raised by the competent
ethics committee, namely that of the Federal State of
Lower Austria. Ninety-seven PsA outpatients (mean age
49.78 years; age range 23–80 years; 49 male, 48 female),
all treated in a private rheumatology office or in a
hospital-based outpatient clinic, were asked to complete
the prototype questionnaire. Demographic details of
these patients are given in Table 1.
The tender joint count (TJC) and swollen joint count
(SJC), including dactylitis and enthesiopathy (15), physi-
cian’s assessment of disease activity on a visual analog
Table 1 Demographic data of patients completing the
prototype six-item questionnaire
Patients (n = 97) Mean Min Max
Gender (f/m) 48/49
Caucasian ethnicity 100%
Age (yrs.) 49.78 20.0 83.0
TJC 2.11 0 19
SJC 1.11 0 10
ESR 15.48 2 60
MDGlob 13.22 0 84





How active is your arthritis today with
respect to joint tenderness and swelling?”
(0 = completely inactive to
10 = extremely active)
“How severe is your arthritis pain today?” (0 = no pain to
10 = unbearable pain)
“How would you describe your general
health today?
(0 = very good to
10 = very bad)
“Did you experience joint (hand)
stiffness on awaking yesterday morning?
If yes, how long was this stiffness?”
(0 = no stiffness to
10 = stiffness the whole day)
“How active do you regard your skin
disease?
(0 = completely inactive to
10 = extremely active)
Final result: (Q1 + Q2 + Q3 + Q4 + Q5)/5 0 - 10
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rate (ESR), and patient satisfaction with disease status
(PatSat: 1 = excellent to 5 = unsatisfactory) were re-
corded [25]. Although not formally validated in PsA pa-
tients, PatSat was used to prove that the questionnaire
really reflected the patient’s view of the disease; a basic
requirement for any patient-related outcome measure.
Statistical evaluation of the prototype questionnaire
Statistical evaluation was carried out using SPSS for
Windows version 11.0. For internal consistency, assess-
ment Cronbach’s alpha was calculated [26]. An alpha
value of 0.70 indicates a standard error of measurement
more than half (0.55) a standard deviation, therefore,
higher values for individual assessments are necessary
[27]. In addition, factor analysis by principal component
analysis was performed to gain insight into the structure
and item loading of the new questionnaire. To assess
convergent validity by relating Stockerau Activity Score
for Psoriatic Arthritis (SASPA) to ESR values, as well as
SJC, TJC, and MDglob, Kendall’s tau was applied [28].
Its computation involves examining every pair of items
and counting the number of pairs that are similarly
ranked (concordant) and the number differently ranked
(discordant) relative to each other on the two variables.
The difference between the number of concordant and
discordant pairs is divided by the total number of pairs.
Tau values range from −1 (100% negative association, or
perfect inversion) to +1 (100% positive association, or
perfect agreement), and a value of 0 indicates the ab-
sence of association [28].
Results
Results for the prototype questionnaire
Cronbach’s alpha as a measure of internal consistency
for the prototype six-item questionnaire was 0.861. Fac-
torial analysis showed a mono-component structure
(Eigenvalue 3.628) as well as an item loading between0.558 (Question 6) and 0.892 (Question 3), indicating
that every question contributed significantly to the ag-
gregate result. Alpha was also calculated after deletion of
one item, with the exception of Question 6, which was
concerned with the severity of the skin disease. Item
loading for Question 1 was 0.736, which appeared to be
the lowest. As statistical reasons did not stand against
and we wanted the new score to be as reliable as neces-
sary, as parsimonious as possible and overall meeting
the needs of practicability, the well-proven five-question
principle and the simple calculation of RADAI-5 was
retained [22].
As Question 6 is regarded as indispensable by all au-
thors, subsequently, Question 1 from the RADAI-5 [22],
targeting the course of the disease during the past
6 months, was removed from the questionnaire, which
resulted in the highest alpha value of 0.849 for a five-item
scale. Kendall’s tau as a measure of agreement between
the six-item questionnaire and the version comprising five
items was 0.908 (p < 0.001), indicating almost perfect
agreement between the two scales.
Analysis of the final questionnaire
The final five-item questionnaire, SASPA, (Table 2), was
handed over to 152 PsA outpatients (mean age 54.02 years;
age range 26–80 years; 82 male, 70 female), resulting in a
total number of 779 completed questionnaires. All pa-
tients were treated in a private rheumatology office or in a
hospital-based outpatient clinic. The demographic details
of these patients are given in Table 3. In accordance with
the analysis of the prototype questionnaire, TJC and SJC,
including dactylitis and enthesiopathy [29], MDglob on a
VAS (0–100), ESR (mm/h) as well as PatSat (1 = excellent
to 5 = unsatisfactory) were recorded. The joint assess-
ments during this observation were performed by three
experienced physicians (BR, JS, and CD) in the outpatient
department and exclusively by BFL in the private office.
In order to avoid high internal variations among the phy-
sicians, consensus meetings concerning joint assessment
Table 3 Demographic data of patients completing SASPA
Patients (n =152) Mean Min Max
Gender (f/m) 70/82
Caucasian ethnicity 100%
Age (yrs.) 54.02 26.0 80.0
TJC 1.92 0 28
SJC 1.24 0 10
ESR 14,828 1 90
MDGlob 8,6 0 65
PatSat 2.46 1 5
DMARDs 126
TNF-Blockers 22
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quality control program of the outpatient department.
For the purpose of this particular study, however, no for-
mal agreement analysis between the physicians was
performed.
Evaluation of the final questionnaire
Statistical evaluation was carried out using SPSS for
Windows version 11.0. For internal consistency, Cronbach’s
alpha was calculated [26]. Fifty-three patients completed
the SASPA questionnaire repetitively. The coefficient of
variation, which estimated the percentage congruency of
repeated measures, was calculated to avoid inclusion of
redundant measurements [30]. In addition, factor analysis
by principal component analysis was performed to gain
insights into the structure and item loading of the new
questionnaire. To assess convergent validity by relating
the SASPA values to ESR values, as well as SJC, TJC, and
MDglob, Kendall’s tau was applied [28]. For assessment of
the sensitivity of the questionnaire to change, SASPA
values before and after initiation of tumor necrosis factor
(TNF) blocker were compared applying a paired t test.
The respective standardized mean difference was calcu-
lated. The relationship between PatSat and the question-
naire was computed by analysis of variance (ANOVA).
Results for the final questionnaire (SASPA)
The SASPA and PatSat values were normally distributed;
therefore, the respective values are given as means and
ranges. The mean SASPA was 2.66 (range: 0–9.2), and
mean PatSat was 2.46 (range: 1–5) for the entire patient
group. The coefficient of variation for repeated comple-
tions was 65.83%.
Cronbach’s alpha for the SASPA questionnaire was
0.875, easily surpassing the limit for substantial internal
consistency in individual assessments. Factorial analysis
by principal component analysis complied with the ex-
pectations and proved the one-dimensional structure of
the questionnaire (Eigenvalue 3.424). Item loading rangedfrom 0.573 (Question 5) to 0.910 (Question 2), indicating
that every item contributed significantly to the aggregate
result.
After proving the internal consistency and analyzing
the factorial structure, the relationship between SASPA
values, derived from a questionnaire not including any
joint count, and SJC, TJC, ESR, as well as MDglob, was
important for assessing convergent validity. Kendall’s tau
for the relationship between SASPA results and SJC was
0.346 (p < 0.001), and between SASPA and TJC it was
0.416 (p < 0.001). MDglob (tau 0.392; p < 0.001) was sig-
nificantly related to SASPA values, while no significant
relationship was found with ESR (tau 0.092) (Figure 1).
ANOVA including Bonferroni’s correction showed a
highly significant relationship between PatSat and SASPA
levels (p < 0.001) (Figure 2).SASPA sensitivity to change
Nineteen patients (mean age 50.6 years; 12 male, 7 female)
began TNF-blocker therapy during this observation.
SASPA values before and a mean 4.1 months after treat-
ment initiation were used to assess the sensitivity to
change of the questionnaire. The mean SASPA at the start
of TNF-blocker therapy was 4.51 (1.6–7.2), and after ther-
apy it was 1.87 (0.2–4.4). This difference appeared to be
highly significant according to a paired sample t test (p <
0.001). The respective standardized mean difference was
2.1, indicating a highly efficacious therapeutic intervention
(Figure 3).Discussion
The main objective of this study was to assess whether a
modified RADAI-5 questionnaire, namely SASPA, could
be used as a fully patient-administered tool for daily PsA
monitoring. SASPA should enable physicians to obtain
reliable information about the disease course to support
treatment decisions. It was not the intention with the
development of SASPA, as with RADAI-5, to compensate
for careful clinical examination [22]. Internal consistency,
as a measure of the extent to which a variable or set of
variables is stable, constitutes the primary prerequisite.
Feasibility and acceptability to physicians and patients are
also important requirements of any assessment tool. To
cover the proposed core set measures for PsA as fully as
possible, while keeping the balance between feasibility
and reliability, it was decided to retain a five-question
structure, as with RADAI-5 [24]. During all the studies
to develop RADAI-5, support could be found for the ar-
guments that RADAI-5 comprises questions targeting a
patient’s pain perception and global health estimate,
which can be seen as surrogates for functionality, and
are likely also to include discomfort caused by enthesio-
pathy [22-24].
Figure 2 Box-plot to demonstrate the relationship between
PatSat and SASPA (p < 0.001 ANOVA, Bonferroni’s correction).
Figure 1 Matrix-scattered plots to demonstrate the relationship between SASPA and TJC, SJC and MDglob. Kendall’s tau for the
relationship between SASPA results and SJC was 0.346 (p < 0.001), between SASPA and TJC, 0.416 (p < 0.001), between SASPSA and MDglob,
0.392 (p < 0.001), and between SASPA and ESR, 0.092 (n.s.).
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tute for physician-derived disease activity scores, which
were developed primarily for research purposes [19]. This
may be expected highly likely also for SASPA in relation
to PsA scores, such as DAPSA and PASDAS [11,12].
As with RADAI-5, SASPA allows better participation
in the care of PsA patients, especially by non-specialists
such as primary care physicians, without having to be
trained in measuring formal joint counts.
PsA in contrast to RA often shows a highly variable
course, including highly active as well as long-lasting in-
active phases [1,2]. Nevertheless, PsA may cause severe
joint destruction and functional loss in some patients
[2]. From the patient’s position, PsA may cause joint
problems, as well as skin manifestations, particularly of
the nails. Moreover, and, of course individually aggravat-
ing, the disease burden’s focus may shift from the
musculoskeletal system to the skin or vice versa [31].
Therefore, we are convinced that rheumatologists and
dermatologists should pay attention to the skin and joint
manifestations before deciding on treatment [32]. This
was why we insisted on including the question targeting
the severity of the skin manifestations. These consider-
ations were the basis for the ultimate decision to leave
Figure 3 Individual courses of SASPA in patients before (SASPA1) and after (SASPA2) initiation of TNF blockers. The bold line denotes
the average (standardized mean difference 2.1).
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ing the past 6 months.
With regard to physician- or patient-reported outcome
measures, SASPA, as for RADAI-5, can be regarded as a
hybrid tool, namely, a tool assessed by patients, compris-
ing domains selected by physicians. Patients agreed that
the SASPA questionnaire was easy and rapid to com-
plete. SASPA has the advantage that the individual
patient – the primary target of all therapeutic interven-
tions – is given the key role with respect to disease ac-
tivity assessment. Beyond that, inter-physician, but also
intra-physician variations in assessing joints or global
disease activity are eliminated, and other pitfalls of joint
counts are avoided [33]. The lower the number of in-
volved joints, the more intra- and inter-observer variance
exerts an influence upon relative assessment tools, which
is of particular importance in PsA, because it constitutes
an oligoarticular disorder in some patients [1,2,33].
Measurement of patient symptoms alone may have an
important shortcoming, namely that symptom levels are
differently evaluated and expressed among patients.
However, physical function on a health assessment ques-
tionnaire, the most frequent patient-reported outcome,
is the measure that is most significant in identifying and
predicting work disability, explaining costs, and predict-
ing mortality in RA – much more effectively than the
other core data set measures [34].
The newly adapted SASPA was investigated for its psy-
chometric properties. Cronbach’s alpha was >0.8, indicat-
ing high internal consistency. Moreover, the questionnaire
proved to be a one-dimensional instrument with some dif-
ferences in item weighing, with the question targeting theseverity of skin disease showing the lowest one. One rea-
son for that could be that PsA patients in our unit have a
highly variable but generally mild psoriatic skin disease,
and primarily seek to reduce the intensity of their joint
complaints.
SASPA was shown to be in moderate agreement, how-
ever significantly correlated, with most of the ACR core
set measures such as TJC, SJC, and MDglob [22,35].
This on the one hand can be regarded as proof of con-
vergent validity, and on the other hand, also as a possi-
bility to eliminate difficulties with joint counts in daily
routine rheumatology [33]. The relationships obtained
here are in line with the results for RADAI-5. One of
the reasons for this moderate agreement may be differ-
ences in patients’ weightings of joint involvement and
physicians’ joint counts. SASPA includes two questions
that target all joints and entheses as a whole, enabling
the patients to weigh their individual burden, which is
not possible if single joints are simply counted, and iden-
tically weighted, for example, the fifth metacarpal joint
being treated in the same manner as the knee.
PsA activity assessment without joint counts has the
advantage of not losing activity by applying certain
counting models. In contrast to RA, no consensus has
yet been reached by which counting models can be ap-
plied in daily routine assessment of individual PsA pa-
tients [36]. The 28-joint count e.g. excludes the foot
joints, which cannot be regarded appropriate in a disease
frequently presenting with an oligoarticular pattern, and
involving the lower extremities. Such joint counting
models may lead to misclassification of some patients
[1,2,33]. To refrain from routine joint counts does not
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place for focused patient evaluation. Nevertheless, as in-
dividualized treatment becomes increasingly important,
patient-related outcome tools could provide substantial
advantages in identifying patients requiring particular
attention.
The sensitivity to change of the questionnaire was
tested in a subgroup of patients starting TNF-blocker
therapy. SASPA was highly sensitive to change, resulting
in a standardized mean difference for the particular
intervention indicating high efficacy. This study was per-
formed in a routine clinical setting, therefore, we took
initiation of TNF-blocker as the standardized therapeutic
intervention and ≥2 months thereafter as the decisive
time point to assess efficacy.
The present study had several limitations. First, the
study was performed in two closely related offices within
a relatively small region. Second, increased self-efficacy,
as a member of a study population, constitutes an im-
portant factor possibly influencing patient’s self- assess-
ment [37]. Third, patients included in this observation
did not have severe skin manifestations. SASPA should
be compared to composite indexes for PsA. We are
confident that the respective results will be in agreement
with those obtained for RADAI-5 and RAPID 3 in RA
patients.
However, as with the other instruments, only stable
low SASPA values can be regarded as indicators of an
uncomplicated disease course [38]. Significant changes,
however, must be appraised with respect to the changes
in the single items and possible coexisting or newly oc-
curring diseases [39]. Our results provide robust evi-
dence that patient-centered disease activity assessment is
reliable and feasible for daily routine monitoring of PsA,
as in RA or ankylosing spondylitis [22,40].Conclusions
During this observational study, we demonstrated that
SASPA, excluding joint counts, could measure PsA ac-
tivity and was sensitive to change. We also demonstrated
the reliability and convergent validity of this question-
naire, derived from RADAI-5. Therefore, we propose the
SASPA questionnaire as an option for routine monitor-
ing of PsA patients, enabling physicians to obtain reli-
able information about disease course and thereby
providing support in treatment decisions.
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